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DOI: http://dx.doi.org/10.1016/j.hemonc.2015.07.004OBJECTIVE/BACKGROUND: Myeloproliferative neoplasms (MPNs) are heterogeneous clonal bone marrow
stem cell disorders and include polycythemia vera (PV), essential thrombocythemia (ET), and idiopathic myelofi-
brosis (IMF) neoplasia. In 2005, the JAK2V617F mutation was identified in Philadelphia chromosome-negative
patients. The aim of this study was to sequence coding exons 12 and 14 of the JAK2 gene in Jordanian patients
with MPN.
METHODS: Both exons 12 and 14 of the JAK2 gene were amplified using polymerase chain reaction from DNA
extracted from 68 blood and bone marrow samples belonging to 57 MPN patients and subjected to DNA
sequencing.
RESULTS: JAK2V617F mutations were detected in 26 of 57 Jordanian patients (45%) with different MPNs.
JAK2V617F was identified in 70%, 31%, and 14% of PV, ET, and IMF cases, respectively. Five men diagnosed
with PV were homozygous for JAK2V617F, whereas the other 21 patients were heterozygous for the mutation.
Neither the JAK2V617F mutation nor any DNA polymorphism in exon 12 or exon 14 of the JAK2 gene was
detected among the 40 leukemic patients. A rare single nucleotide polymorphism, c.1860CﬁT
(rs375442615), was detected in one patient with ET.
CONCLUSION: This study is the first molecular investigation of the JAK2 gene in Jordan. We successfully iden-
tified the JAK2V617F mutation in Jordanian patients with Philadelphia chromosome-negative MPNs. Our results
provide a basis for the early detection of this mutation and simplify the diagnostic workup for these disorders at
the molecular level.
KEYWORDS: JAK2 mutations; Jordan; Myeloproliferative neoplasms; Polycythemia vera; V617FIn accordance with the 2008 World HealthOrganization (WHO) hematopoietic tumor clas-siﬁcation, myeloproliferative neoplasia (MPN)
disorders were reclassiﬁed into two groups: chronic
myelogenous leukemia (CML), Philadelphia
chromosome-positive (Ph+) disease, and
Philadelphia chromosome-negative (Ph) disease.1
The classical Ph MPNs include essentialthrombocythemia (ET), polycythemia vera (PV),
and idiopathic myeloﬁbrosis (IMF).1,2 Proliferation
of one or more of myeloid, megakaryocyte, and ery-
throid trilineage cells causes PV, ET, and IMF.1
With exception of the identiﬁcation of the Ph+ in
95% of patients with CML, the molecular basis for
the other MPNs was unknown.3 In 2005, four differ-
ent research groups identiﬁed the c.1849GﬁTarter 2015
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transversion mutation in exon 14 of the JAK2 gene in
Ph MPN patients.4–7 The c.1849GﬁT mutation
resulted in replacement of valine residue 617 by a
bulky phenylalanine amino acid (V617F) in the
Janus kinase-2 (JAK2) protein. Herein, we refer to
the mutation as JAK2V617F.
Similar to others JAK-family proteins, JAK2 exhi-
bits seven homologous domains numbered JH1–7.8
The JAK2V617F mutation is located in the JAK2
gene-coding region of the pseudokinase (JH2)
domain. The pseudokinase domain has an inhibitory
role against the catalytic activity of the kinase (JH1)
domain.8 The JAK2V617F mutation is predicted
to disrupt inhibitory function of the pseudokinase
domain, thereby increasing kinase activity indepen-
dent of the pseudokinase domain, which strongly sug-
gests that the JAK2V617F is a gain-of-function
mutation.4–7
Additional screening for mutations in other JAK2
exons from PV patients negative for the JAK2V617F
mutation revealed four novel mutations in exon
12.9,10 The four mutations were clustered and
affected codons 538–543 of the JAK2 gene. Several
additional mutations in exons 12–15 of the JAK2
gene have also been identiﬁed in patients clinically
suspected to have MPN.11
Given that the JAK2V617F mutation in exon 14
and the other mutations identiﬁed in exon 12 are
observed in almost all PV patients, several mutations
in theMPL and CALR genes were subsequently iden-
tiﬁed in ET and IMF patients, emphasizing the
genetic heterogeneity of these two disorders relative
to PV disease.12,13
Several genome-wide association studies were per-
formed following the identiﬁcation of the JAK2V617F
somatic mutation in MPN disorders to determine
whether a germline haplotype could contribute to
the MPN phenotype and predisposition among the
three neoplasms. Single nucleotide polymorphism
(SNP) genotyping of a 280-kb genomic region on
chromosome 9 identiﬁed the haplotype designated
as 46/1. Four intronic SNPs of this haplotype located
within the 30-end of the JAK2 gene were found to be
more frequently inherited in cis with the JAK2V617F
mutation in MPN patients.14,15
Two germline mutations (JAK2R564Q in exon 13
and JAK2V617I in exon 14) were recently identiﬁed
in two ET families.16,17 In light of the discovery of
these two new familial germline mutations, the 46/1
haplotype predisposition, and the acquired
JAK2V617F mutation in the JAK2 gene, the role of
the JAK2 mutation in both somatic and germline cells
has been conﬁrmed in MPN pathogenesis.Hematol Oncol Stem Cell Ther 8(4) Fourth Quarter 2015In November 2011, ruxolitinib, the ﬁrst drug to
treat MPN with JAK2V617F, was approved by the
U.S. Food and Drug Administration. Clinical trials
demonstrated that ruxolitinib is effective in relieving
many of the myeloﬁbrosis-related symptoms, most
notably spleen size reduction.18,19 The JAK2V617F
mutation frequency has been reported inMPNpatients
in several populations, including Lebanese and
Egyptian.20,21 Here, we report for the ﬁrst time the
frequency of this mutation in JordanianMPN patients.MATERIALS AND METHODS
Study population
A total of 57 Jordanian patients diagnosed with MPN
were involved in this study. Twenty-seven patients
exhibited PV, 16 were diagnosed with ET, and 14
had IMF. Forty-two patients (23 with PV, 14 with
ET, and 5 with IMF) were available at the time of
study and blood samples were collected from these
patients. The patients were treated at the internal
medicine clinic at both Princess Basma Hospital
and King Abdullah University Hospital located in
Irbid city. Twenty-six archival formalin-ﬁxed
parafﬁn-embedded bone marrow biopsies (6 with
PV, 8 with ET, and 12 with IMF) were obtained
from the pathology department at King Abdullah
University Hospital. Eleven of 57 patients had both
blood and bone marrow samples (2 with PV, 6 with
ET, and 3 with IMF). The median age of the case ser-
ies was 58 (14–82 years). Forty-seven of the 57
patients were diagnosed with MPNs by applying the
major and minor criteria depicted by the 2001
WHO classiﬁcation.22–24 The other 10 patients (8
ET and 2 IMF) were referred to the Center for
molecular diagnostic purposes. These were suspected
to have ET and IMF, depending on clinical and lab-
oratory ﬁndings, and never investigated at the time
of sample collection for bone marrow histopathologi-
cal ﬁndings. All samples were collected between
January 2007 and early January 2008 and were Ph
using G-banding routine karyotyping.
Furthermore, 40 samples were collected from
patients previously diagnosed at King Abdullah
University Hospital and Jordan University Hospital
with acute or chronic leukemias, including 14
patients with chronic lymphocytic leukemia (CLL),
11 with acute lymphoblastic leukemia (ALL), eight
with chronic myeloid leukemia (CML), and seven
with acute myeloid leukemia (AML). The study
protocol was approved by the local ethics committee
at Jordan University of Science and Technology
and all patients gave written informed consent.161
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The genomic DNA from patients was extracted from
whole blood and from three to ﬁve 5-lm-thick histo-
logical sections derived from individual formalin-ﬁxed
parafﬁn-embedded bone marrow blocks using the
QIAamp DNA Blood Mini Extraction Kit and the
QIAmp Tissue DNA Extraction Mini Kit according
to manufacturer recommendations (Qiagen GmbH,
Hilden, Germany).
The polymerase chain reaction (PCR) primers
used to amplify exons 12 and 14 were designed using
Primer3 software (http://frodo.wi.mit.edu/cgi-bin/
primer3/primer3_www.cgi) according to the
GenBank accession numbers for JAK2 cDNA
(NM_004972.3) and for genomic DNA
(NG_009904.1). Exon 12 primers had the following
sequences: forward [50-TCTGATGTACCAA-
CCTCACCA-30] and reverse [50-CATGAATGT-
AAATCAAGAAAACAGATG-30]. Exon 14
primers had the following sequences: forward [50-
TGGCAGAGAGAATTTTCTGAACT-30] and
reverse [50-TGTTTGGGCATTGTAACCTTC-
30]. PCR was performed in a ﬁnal volume of 25 lL
in an iCycler Thermal Cycler (Bio-Rad, Hercules,
CA, USA). Cycling conditions for amplifying the
two exons from DNA extracted from blood and tissue
samples are available on request.
The PCR products were puriﬁed using a PCR
puriﬁcation kit (Bio Basic, Markham, ON, Canada)
and the puriﬁed PCR products were sequenced using
the BigDye Terminator Cycle Sequencing Kit version
3.1 (Applied Biosystems, Foster City, CA, USA).
Excess Dye Deoxy terminator was removed from
the DNA sequencing reaction by cleaning the PCR
sequencing products using the DyeEx 2.0 spin
puriﬁcation kit (Qiagen). Finally, the samples were
sequenced on an ABI 310 DNA sequencer
(Applied Biosystems) and the sequencing results
were analyzed using ChromasPro software version
1.34. (Technelysium Pty Ltd., South Brisbane,
Australia).RESULTS
Both exons 12 and 14 of the JAK2 gene were ampli-
ﬁed by PCR from DNA extracted from 68 blood and
bone marrow samples belonging to 57 MPN patients
included in this study. Similarly, the DNA from 40
leukemia patients were ampliﬁed. The ampliﬁed frag-
ments were of the expected size for exon 12 (165 bp)
and exon 14 (382 bp).
In 26 (45%) of the 57 Jordanian patients with
MPN, the c.1849GﬁT mutation (JAK2V617F) inJAK2 exon 14 was detected by sequence analysis of
the PCR product generated from peripheral blood
and/or bone marrow biopsies (Figure 1 and
Table 1). The JAK2V617F mutation detection rate
was highest among the PV (70%) samples, followed
by the ET and IM samples (Table 1). Thirteen of
the 18 male PV patients tested were JAK2V617F pos-
itive and six of nine PV females screened were carriers
(heterozygous) for the same mutation (Table 1). Five
of 13 male PV patients were homozygous for the
c.1849T mutant allele and the remaining eight male
patients were heterozygous. One patient with ET
who was a carrier for the wild-type genotype of the
JAK2V617F mutation was heterozygous for the
c.1860CﬁT polymorphism (Figure 2) in his blood
sample and homozygous for the wild-type C allele
in his bone marrow DNA sample. The c.1860CﬁT
polymorphism, which is located in exon 14, is a silent
polymorphism that converts the Asp620 GAC codon
into a GAT Asp codon (JAK2D620D). For the other
10 MPN patients (2 with PV, 5 with ET, and 3 with
IMF) for whom we had DNA samples from both
bone marrow biopsies and blood, the genotyping
results for nine samples were in agreement between
both blood and bone marrow biopsy DNA samples,
with one ET patient heterozygous for the
JAK2V617F mutation in his blood and wild-type in
his bone marrow DNA sample. All 57 MPN patients
screened for exon 12 exhibited no mutation in this
exon of the JAK2 gene. None of the CML, CLL,
ALL, or AML patients had the JAK2V617F mutation
or any other polymorphic changes in exon 14 of the
JAK2 gene.DISCUSSION
This is the ﬁrst molecular JAK2 gene study on
Jordanian patients with MPN. In this study, we iden-
tiﬁed the JAK2V617F mutation in exon 14 of the
JAK2 gene in 26 (45%) of 57 Jordanian patients with
MPN. The mutation was detected in 70% and 31% of
our PV and ET population, respectively, which are
similar frequencies to those reported by others.6,7
However, the mutation rate in this study among
Jordanians with MPN was lower than that reported
in other populations, including Lebanese and
Egyptian studies.20,21
The lower mutation percentage in both PV and
ET Jordanian patients could be explained by some
of these patients possibly being misdiagnosed with
MPN when they may have severe secondary reactive
conditions, such as erythrocytosis and thrombocyto-
sis.25 Additionally, owing to the nature of theHematol Oncol Stem Cell Ther 8(4) Fourth Quarter 2015
Figure 1. DNA sequence chromatograms of the c.1849GﬁT (JAK2V617F) mutation in exon 14 of the JAK2 gene. (A) c.1849G homozygous wild-type;
(B) c.1849GﬁT heterozygous mutant; (C) c.1849T homozygous mutant. The arrows indicate mutation locations.
Table 1. Frequency of JAK2V617F mutation in Jordanian MPN patients.
Characteristics Polycythemia
vera
Essential
thrombocythemia
Idiopathic
myelofibrosis
Number 27 16 14
Men/women
(n)
18/9 8/8 10/4
Median age
(range)
62 (28–82) 47 (14–80) 61.5 (31–79)
V617F mutant
(n)
19 5 2
Men/women
(n)
13/6 2/3 2/0.0
V617F mutant
(%)
70 31 14
Hematol Oncol Stem Cell Ther 8(4) Fourth Quarter 2015
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mutation restricted to the myeloid lineage, genomic
DNA extracted from either blood or bone marrow
samples, as in our study, is often is a mixture of neo-
plastic and normal hematopoietic cell DNA.26 Thus,
there is a high likelihood of missing ampliﬁcation of
the mutant T allele in an excess of wild-type G allele.4
Five Jordanian PV patients were homozygous for
the JAK2V617F mutation. Homozygous genotypes
have been reported in at least one-third of PV
patients due to loss of heterozygosity on chromosome
9p followed by duplication of the lost 9p portion by
mitotic recombination.4,5
Although a study reported that DNA derived
from peripheral blood and bone marrow exhibits
equivalent detection levels when screened for
JAK2V617F, the inconsistent genotyping results of
two ET patients in blood cells collected recently,
but not in a bone marrow biopsy taken 3 years ago,
is noteworthy. This inconsistency in the genotyping
results could be due to the lower detection limit for163
Figure 2. c.1860CﬁT (JAK2D620D) polymorphism (rs375442615) in exon 14 of the JAK2 gene. (A) c.1860C homozygous wild-type; (B) c.1860CﬁT
heterozygous mutant. The solid arrows indicate c.1860CﬁT polymorphism locations and the dashed arrows indicate the wild-type JAK2V617F
sequence.
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we used compared with other sensitive methods, such
as allele-speciﬁc PCR or reverse transcription
polymerase chain reaction (RT-PCR).27 Transition
from a JAK2V617F-negative to a JAK2V617F-positive
MPN has not been reported to date, even after a very
long follow up. However, because of the effect of time,
an increase in the number of mutated granulocytes
carrying the mutated JAK2V617F allele may increase
the likelihood of detecting the mutation using
sequencing techniques, whereas patients in the early
stage may be falsely negative for JAK2V617F.28
The c.1860CﬁT variant identiﬁed in one ET
patient in this study was also found in the National
Center for Biotechnology Information Variation
Database (http://www.ncbi.nlm.nih.gov/snp; SNP
ID: rs375442615). Unfortunately, there was no
RNA from the patient at the time of the study to test
this mutation by RT-PCR for splicing errors.
However, several observations suggest that the
c.1860CﬁT (JAK2D620D) variant may not be a rare
polymorphism, but could represent a silent mutation.
The evidence for these observations is as follows: (a)
the T allele was not observed in the DNA of 40 leu-
kemic patients, who functioned in this study as a con-
trol for the absence of JAK2 mutation; (b) the T allele
is only ﬁve nucleotides from the ‘‘gt’’ donor site ofintron 14, which might interfere with the normal
splicing processes of the JAK2 gene; (c) the frequency
of the T allele is 0.12% according to the 1000
Genomes Project (http://www.1000genomes.org/);
and (d) the mutation occurred in the codon associated
with D620, a hot-spot mutation residue in the JAK2
protein.29
We did not detect JAK2V617F or any variation in
exons 12 and 14 of the JAK2 gene in the 40 leukemia
patients we screened. JAK2V617F has not been
reported in any of the lymphoid lineage malignancies,
however, in CML, signiﬁcant portions (10%) of the
patients are carriers of the JAK2V617F mutation.30
Additionally, four AML patients were found to be
JAK2V617F positive, however, three had a preceding
MPN condition.31 It is well documented that leuke-
mic transformation occurs in 1%, 2%, and 10% of
the PV, ET, and IMF patient populations,
respectively.32
Although the sensitivity of the JAK2 mutation
assay methods was reported as a contributing factor
to variation between several studies, we believe, due
to some study limitations, that the incidence of mainly
the ET and IMF conditions may not reﬂect the real
incidence of the JAK2 mutations in Jordanians.4–7
These limitations include the small cohort of patients
compared with other regional studies and the fact thatHematol Oncol Stem Cell Ther 8(4) Fourth Quarter 2015
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clinical classiﬁcations of MPN patients in this study
were carried out at three different referral centers,
where overlapping clinical features between MPNs
might be measured differently.20,21,33
Additionally, there were eight ET and two IMF
bone marrow specimens not investigated by patholo-
gists at the time of sample collection, which in
histopathology investigations is an important differen-
tial diagnostic for both conditions.23,24,33,34 Finally,
another limitation was the exclusion of Ph+ by using
routine karyotyping, where other associated MPN
cryptic and submicroscopic chromosomal abnormali-
ties could be missed.35CONCLUSION
In summary, we have identiﬁed JAK2V617F in several
Jordanian patients with MPN disorders. TheseHematol Oncol Stem Cell Ther 8(4) Fourth Quarter 2015results will facilitate the molecular genetic diagnosis
of PV, ET, and IMF disorders in Jordan.
Additionally, Jordanian MPN patients lacking the
JAK2V617F mutation may, nevertheless, bear muta-
tions in other genes recently identiﬁed and found to
be mutated in MPN patients.12,13CONFLICT OF INTEREST
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